Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | CA12 | O43570 | 1/20 | 0.75 |
| ▸ | CA1 | P00915 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.75 |
| ▸ | CA3 | P07451 | 1/20 | 0.75 |
| ▸ | CA4 | P22748 | 1/20 | 0.75 |
| ▸ | CA6 | P23280 | 1/20 | 0.75 |
| ▸ | CA5A | P35218 | 1/20 | 0.75 |
| ▸ | CA7 | P43166 | 1/20 | 0.75 |
| ▸ | CA9 | Q16790 | 1/20 | 0.75 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.75 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.75 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079098 | 1.00 | LMNA (0.75) | LMNACA12CA1CA2CA3 | |
| SCHEMBL1877216 | 1.00 | LMNA (0.75) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4942841 | 0.86 | LMNA (0.61) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19139156 | 0.86 | LMNA (0.61) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13788532 | 0.86 | LMNA (0.75) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL118843 | 0.86 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13788510 | 0.86 | LMNA (0.75) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL373194 | 0.86 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL5072485 | 0.86 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levitiracetam SCHEMBL61493 | 0.86 | LMNA (1.00) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115734964-B | Levetiracetam Process for the preparation of intermediates | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| WO-2024258522-A1 | PROCESS FOR THE PRODUCTION OF LEVETIRACETAM AND INTERMEDIATES THEREOF | SUZHOU BRIGHTHOPE PHARMATECH CO., LTD (CN) | 2024-12-19 | — | — | WO | claimed |
| CN-118050445-A | Method for detecting glycerol parahydroxybenzoate in levetiracetam oral liquid | 湖南省湘中制药有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-118028275-A | Lactamase mutant for amide synthesis and application thereof | 江南大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117867528-A | Method for preparing levetiracetam drug intermediate by electrocatalytic oxidation of manganese-doped nickel selenide catalyst | 浙江工业大学 | 2024-04-12 | — | — | CN | claimed |
| CN-117677605-A | Process for preparing levetiracetam and intermediates thereof | 维生源知识产权有限责任公司 | 2024-03-08 | — | — | CN | claimed |
| EP-4329929-A2 | GAS-LIQUID-SOLID AND LIQUID-SOLID REACTOR CASCADE FOR CARRYING OUT CONTINUOUS-FLOW CHEMICAL REACTIONS UNDER HIGH PRESSURE AND/OR HIGH TEMPERATURE | IPSOMEDIC (FR) | 2024-03-06 | — | — | EP | claimed |
| CN-113272275-B | Preparation method of levetiracetam intermediate | 浙江华海药业股份有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-116837047-A | Method for preparing (S) -alpha-ethyl-2-oxo-1-pyrrolidine acetic acid | 浙江华海药业股份有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116655513-A | Preparation method of high-purity levetiracetam | 重庆圣华曦药业股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20090069575-A1 | Process For The Preparation Of (S)-Alpha-Ethyl-2-Oxo-1-Pyrrolidineacetamide And (R)- Alpha-Ethyl-2-Oxo-Pyrrolidineacetamide | APOTEX PHARMACHEM INC. (CA) | 2009-03-12 | — | — | US | claimed |
| CN-101333180-A | Method for preparing levetiracetam intermediate | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2008-12-31 | — | — | CN | claimed |
| CN-101270070-A | Method for preparing (S)-alpha-ethyl-2-oxo--1-pyrrolidine ethanamide with high optical purity | SHANGHAI ECUST BIOMEDICINE CO (CN) | 2008-09-24 | — | — | CN | claimed |
| EP-1828120-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (S)-ALPHA-ETYL-2-OXO-1-PYRROLIDINEACETAMIDE AND (R)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE | Apotex Pharmachem Inc. (CA) | 2007-09-05 | — | — | EP | claimed |
| WO-2006127300-A1 | SYNTHESIS OF (S)-α-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE | CAMBREX CHARLES CITY, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006053441-A1 | IMPROVED PROCESS FOR THE PREPARATION OF (S)-ALPHA-ETYL-2-OXO-1-PYRROLIDINEACETAMIDE AND (R)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE | APOTEX PHARMACHEM INC. (CA) | 2006-05-26 | — | — | WO | claimed |
| CN-1015541-B | PROCESS FOR PREPARING (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE | UCB SA (BE) | 1992-02-19 | — | — | CN | claimed |
| CN-1015542-B | Process for the preparation of -alpha-ethyl-2-oxo-1-pyrrolidineacetamide | UCB SA (BE) | 1992-02-19 | — | — | CN | claimed |
| CN-85105301-A | (S)-preparation method of alpha-ethyl-2-oxo-1-pyrrolidine acetamide | — | 1987-01-14 | — | — | CN | claimed |
| CN-85105307-A | (R)-preparation method of alpha-ethyl-2-oxo-1-pyrrolidine acetamide | — | 1987-01-14 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069575-A1 | Process For The Preparation Of (S)-Alpha-Ethyl-2-Oxo-1-Pyrrolidineacetamide And (R)- Alpha-Ethyl-2-Oxo-Pyrrolidineacetamide | RPS4X, BRIX1, RIOX2 | LMNA 3526/4885CA12 1708/4885CA1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.